Akademik Veri Yönetim Sistemi
50th ESCP Symposium on Clinical Pharmacy, Polypharmacy and ageing - highly individualized, interprofessional, person-centered care, Praha, Çek Cumhuriyeti, 19 - 21 Ekim 2022, cilt.44, ss.1513-1514
Predicting acceptance and intention for receiving boost dose of covid vaccine among pregnant women using Health Belief model
Background and Objective: The COVID-19 pandemic has stretched public health. Pregnant women with COVID-19 infection are at increased risk for poorer health outcomes, preterm birth, and pregnancy loss. Despite limited safety data, COVID-19 vaccines are safe for use in pregnancy, as they do not contain a live attenuated virus. However, vaccine hesitancy is a complex phenomenon and context specific, varying across time, place, and vaccines. Predicting vaccine confidence, acceptance and reluctance are important measures to assist decision makers in setting policies dealing with any worrisome regarding a boost COVID-19 dose. The aim of this study was to assess the acceptance and intention to receive a boost dose (s) of COVID-19 vaccine using health belief model (HBM) among pregnant women in Istanbul, Turkey.
Method: This was a descriptive, cross-sectional study conducted among a convenient sample size of pregnant women attending the obstetrics and gynaecology hospital clinic of Acıbadem Mehmet Ali Aydınlar University, Faculty of Medicine in Istanbul, Turkey, using a validated structured questionnaire consisting of 8-item demographic characteristics, and 14-item questionnaire assessing acceptance and intention to receive a boost dose (s) of COVID-19 vaccine using HBM scale (intent, knowledge, worry degree, perceived necessity and vaccination history).
Main outcome measures: Frequency for acceptance and intention to receive a boost dose (s) of COVID-19 vaccine using health belief model (HBM) scale.
Results: A total of 38 pregnant women patients with an average age of 31.9 ± 5.1 years and gestational age 31.7 ± 5.6 weeks were included. Majority of the respondents had university and secondary education level (60.5%), had no comorbid disease condition (79%). 57.9% of the respondents had no history of COVID-19 infection, 86.8% were fully vaccinated, of whom 60.5% received full doses of Pfizer vaccination (vaccination history). Nealy half of the respondents (55.3%) were not worried about the vaccine side effects (worry degree) and 68.4% (n = 26) did not report any side effects after vaccination. 66.6% (8/12) reported mild side effects after vaccination which lasted for 24 h. 47.3% of the participants reported that they provided with information to control symptoms of side effects after vaccination (knowledge). Nealy half of the respondents (52.7%) worried from being re-infected. 28.9% were provided full information about the importance of a boost vaccine dose (perceived necessity). 57.9% and 7.69% reported a strong intention to receive a boost vaccine dose and from the same previous brand, respectively (intent).
Conclusion: This study revealed a high rate of acceptance and intention to receive a boost vaccine dose despite the dispositional worry. Therefore, clinicians can outline the potential benefits of vaccination weighed against the potential risks which motivates vaccination behaviours among pregnant women during pandemic.
Disclosure of Interest: None Declared